Second Sight Medical Products (NASDAQ:EYES) and Aradigm (OTCMKTS:ARDMQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.
Insider & Institutional Ownership
3.6% of Second Sight Medical Products shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 4.5% of Aradigm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Second Sight Medical Products has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Aradigm has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500.
This is a summary of recent recommendations for Second Sight Medical Products and Aradigm, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
Second Sight Medical Products currently has a consensus price target of $2.50, suggesting a potential upside of 33.69%. Given Second Sight Medical Products’ higher probable upside, analysts clearly believe Second Sight Medical Products is more favorable than Aradigm.
Earnings & Valuation
This table compares Second Sight Medical Products and Aradigm’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Second Sight Medical Products||$3.38 million||12.79||-$33.59 million||($1.91)||-0.98|
|Aradigm||$14.47 million||0.05||-$10.70 million||N/A||N/A|
Aradigm has higher revenue and earnings than Second Sight Medical Products.
This table compares Second Sight Medical Products and Aradigm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||N/A||-977.63%||-291.02%|
About Second Sight Medical Products
Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.